South Africa's SAHPRA's Clinical Guideline for Human Medicines Registration
- Sharan Murugan
- 17 hours ago
- 4 min read
The registration of human medicines is a complex process that requires comprehensive scientific evidence demonstrating that a product is safe, effective, and manufactured to acceptable quality standards. To support applicants seeking registration of human medicines in South Africa, SAHPRA has issued the guidance Clinical Guideline.
The guideline provides detailed information on the clinical evaluation pathways available for human medicines and outlines the documentation, data requirements, and scientific evidence expected to support registration applications. It also provides clarity regarding the evaluation of new chemical entities, generic medicines, extension applications, and reliance-based review pathways.
The Purpose of the Clinical Guideline
The primary purpose of the guideline is to provide applicants with clear direction on the review pathways used by SAHPRA during the clinical evaluation of medicines. The document explains the types of data that should be submitted for different categories of applications and describes how clinical and non-clinical information is assessed during the registration process.
The guideline also establishes a structured approach for evaluating medicines while ensuring consistency in regulatory decision-making.
Scope of the Guideline
The Clinical Guideline applies to human medicines within Categories A and D and covers both new registration applications and certain amendments to existing registrations. The guideline serves as a key reference document for applicants preparing registration submissions and provides a framework for understanding how SAHPRA evaluates clinical evidence.
Types of Applications Covered
Different categories of medicines require different levels of supporting evidence. The guideline therefore distinguishes between several application types that may be submitted for evaluation.
New Chemical Entity Applications
New Chemical Entity (NCE) applications involve medicines containing active substances that have not previously been registered. These applications generally require comprehensive non-clinical and clinical data to support the proposed indication, dosage regimen, formulation, and overall benefit-risk profile.
Generic and Multisource Applications
Generic medicines are intended to provide therapeutic alternatives to existing products. To support approval, applicants must demonstrate that the generic product performs similarly to an approved reference medicine.
Evidence supporting these applications may include:
Comparative bioavailability studies
Bioequivalence studies
Comparative dissolution studies
Clinical data where necessary
Other comparative evidence supporting efficacy
The objective is to demonstrate that the generic product can be expected to provide comparable therapeutic outcomes to the reference product.
Pharmaceutical Equivalence Applications
Pharmaceutical equivalent products contain the same active substance in the same dosage form and strength and are administered through the same route as the reference product.
Applicants must generally demonstrate bioequivalence and provide evidence that the product meets the requirements for therapeutic equivalence.
Pharmaceutical Alternatives and Extension Applications
The guideline also addresses pharmaceutical alternatives and extension applications. These products may contain the same active pharmaceutical moiety but differ in dosage form, chemical form, strength, or other characteristics.
Examples of extension applications include:
Extension Category | Example |
New Strength | Addition of a different dosage strength |
New Route of Administration | Introduction of an alternative route |
Pharmacokinetic Change | Modified-release formulation |
Bioavailability Change | Reformulation affecting absorption |
Active Substance Change | Changes involving active ingredient characteristics |
Such applications may require additional clinical evidence to demonstrate that the proposed changes do not negatively affect safety or efficacy.
Clinical Review Pathways
One of the most significant aspects of the guideline is the introduction of defined review pathways that allow SAHPRA to apply different levels of assessment depending on the nature of the application and available supporting evidence.
Full Review
The Full Review pathway involves a comprehensive assessment of all submitted information. During a Full Review, SAHPRA evaluates all relevant non-clinical and clinical data submitted within the dossier. This includes detailed reviews of pharmacology, toxicology, pharmacokinetics, clinical efficacy, safety information, and overall benefit-risk assessments.
Abridged Review
The Abridged Review pathway is intended to improve regulatory efficiency for products that have already received approval from recognized regulatory authorities. Under this approach, SAHPRA can utilize existing assessments conducted by trusted authorities while still performing its own independent evaluation of the application. This pathway helps reduce review timelines while maintaining confidence in the scientific assessment process.
Verified Review
The Verified Review pathway is primarily intended for multisource and generic products where the active pharmaceutical ingredient has already been registered by SAHPRA. Rather than conducting a complete reassessment of clinical evidence, the focus is placed on verifying consistency with approved reference information, particularly from a clinical safety perspective.
Non-Clinical Study Requirements
Non-clinical studies provide essential information regarding the biological activity and safety profile of a medicine before it is administered to humans.
Clinical Study Requirements
Clinical studies provide the primary evidence used to establish the safety and efficacy of medicines intended for human use. SAHPRA expects all clinical studies to be conducted according to internationally accepted Good
Documentation Requirements for Registration
A successful registration application requires comprehensive supporting documentation that enables SAHPRA to evaluate all aspects of the product.
Depending on the review pathway, applicants may be required to provide:
Application cover letters
Professional Information (PI)
Patient Information Leaflets (PIL)
Administrative documentation
Risk Management Plans
Safety reports
Clinical expert reports
Non-clinical summaries
Clinical study summaries
Full study reports
Pharmacology data
Toxicology data
For reliance-based pathways, applicants may also need to provide documentation demonstrating previous approvals and supporting assessment reports from recognized regulatory authorities. Careful preparation of these materials is essential for facilitating an efficient review process and reducing the likelihood of regulatory queries.
For pharmaceutical companies and regulatory professionals, a thorough understanding of these requirements is essential for preparing successful registration submissions and supporting timely access to safe and effective medicines within the South African market.
Comments